These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 445975)

  • 41. Clinical cardiac electrophysiological assessment of indoramin.
    Butrous GS; Camm AJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S137-43. PubMed ID: 2423787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the renal effects of indoramin and prazosin.
    Strandhoy JW
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S151-5. PubMed ID: 2423789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hypotensive action of DL-(methylene-3-4) phenyl 2 hydroxy-2-acetamidine hydrocloride (LL-1418)].
    Duteil J; Sautai M; Pessonnier A; Gombert R; Assous E
    Therapie; 1969; 24(4):723-33. PubMed ID: 5822010
    [No Abstract]   [Full Text] [Related]  

  • 44. Cardiovascular effects of indoramin in man--a dose ranging study.
    Nicholls DP; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1983 Jan; 15(1):31-6. PubMed ID: 6849741
    [No Abstract]   [Full Text] [Related]  

  • 45. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pharmacology of 2-(ethylamino)-2-(2-thienyl)-cyclohexanone-HCl (CI-634).
    Chen G; Ensor CR; Bohner B
    J Pharmacol Exp Ther; 1969 Jul; 168(1):171-9. PubMed ID: 4978323
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical evaluation of indoramin, a new antihypertensive agent.
    Lewis PJ; George CF; Dollery CT
    Eur J Clin Pharmacol; 1973 Dec; 6(4):211-6. PubMed ID: 4359995
    [No Abstract]   [Full Text] [Related]  

  • 48. Proceedings: Initial clinical experience with indoramin, a new antihypertensive agent.
    Royds RB
    Br J Pharmacol; 1972 Feb; 44(2):379P-380P. PubMed ID: 4668635
    [No Abstract]   [Full Text] [Related]  

  • 49. Indoramin in the hypertensive patient with concomitant disease: clinical experience.
    Rosendorff C
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S93-7. PubMed ID: 2423808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular effects of a new antihypertensive agent in several species.
    Salvati P; Caravaggi AM; Lamberti E; Monteggia M; Bianchi G
    Arzneimittelforschung; 1983; 33(8):1098-106. PubMed ID: 6685486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indoramin as second step therapy in the management of benign essential hypertension.
    Montenero AS; Mazzari M; Schiavoni G; Manzoli U; Gherardi S
    Pharmatherapeutica; 1983; 3(6):417-21. PubMed ID: 6353433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Central sympathetic reactivity inhibited by indoramin.
    Davison M; Koss M
    Eur J Pharmacol; 1980 Nov; 68(2):193-6. PubMed ID: 7202486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Study of peripheral antiserotonin properties of some new indol derivatives].
    Pidevich IN; Senova ZP; Fedorova IB
    Farmakol Toksikol; 1971; 34(2):155-9. PubMed ID: 5563384
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacology of Go-1002.
    Grewal RS; Kaul CL; David J
    J Pharmacol Exp Ther; 1968 Apr; 160(2):268-76. PubMed ID: 4384786
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of indoramin on finger circulation in patients with Raynaud disease.
    Clement DL; Duprez D; De Pue N
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S84-7. PubMed ID: 2423806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of indoramin in man.
    Draffan GH; Lewis PJ; Firmin JL; Jordan TW; Dollery CT
    Br J Clin Pharmacol; 1976 Jun; 3(3):489-95. PubMed ID: 788751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparative study of indoramin versus dihydroergotamine in the preventive treatment of migraine].
    Pradalier A; Dry J; Loisy B; Meininger V; Vicaut E; Mirabaud C; Levy M
    Therapie; 1988; 43(4):293-7. PubMed ID: 3055407
    [No Abstract]   [Full Text] [Related]  

  • 58. [Antihypertensive study of xingnao qingxuan recipe].
    Zhou Y; Hu X; Zhao Z; He X; Peng Q; Peng X; Huang L; Sun B; Cao R
    Zhongguo Zhong Yao Za Zhi; 1999 Aug; 24(8):483-8, 511-2. PubMed ID: 12205868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bamethan A competitive betamimetic drug.
    Marmo E; Saini RK; Caputi AP
    Res Commun Chem Pathol Pharmacol; 1974 Jun; 8(2):247-72. PubMed ID: 4152789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.